Cutaneous Vasculitis: Causes, Symptoms & Treatment Insights
Inflammation of skin blood vessels causing purpura, nodules, and ulcers: classification, causes, clinical features, and management strategies.
Author: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand. Reviewed: 2023-10-01. Synonyms: Skin vasculitis, cutaneous leucocytoclastic vasculitis, cutaneous small vessel vasculitis (CSVV).
What is cutaneous vasculitis?
Cutaneous vasculitis refers to inflammation specifically targeting the blood vessels within the skin, primarily affecting post-capillary venules in the dermis. This condition manifests as visible skin lesions due to leakage of red blood cells, fibrin, and inflammatory cells from damaged vessels, resulting in hallmark signs such as palpable purpura, petechiae, or subcutaneous nodules. Unlike systemic vasculitis, cutaneous vasculitis is often confined to the skin, though it may occasionally signal underlying systemic disease. The inflammation typically involves small vessels and is characterized histologically by leukocytoclastic vasculitis, featuring neutrophil infiltration, karyorrhexis, and fibrinoid necrosis. Early recognition is crucial, as most cases are self-limited, resolving within weeks to months, but severe or recurrent episodes may require intervention.
Who gets cutaneous vasculitis (epidemiology)?
Cutaneous vasculitis affects individuals across all ages, with a peak incidence in adults aged 40–60 years, showing a slight female predominance. It is relatively uncommon, with an estimated annual incidence of 15–20 cases per 100,000 population. Risk factors include recent infections (e.g., upper respiratory tract infections), medication exposure (e.g., antibiotics, NSAIDs), autoimmune diseases, and malignancies. Children may present with forms resembling IgA vasculitis (Henoch–Schönlein purpura), often triggered by infections. Genetic predispositions are rare, but HLA associations have been noted in some immune complex-mediated cases. Environmental triggers like cold exposure or trauma can exacerbate lesions in susceptible individuals.
What causes cutaneous vasculitis?
The pathogenesis involves immune-mediated damage to vessel walls, predominantly through immune complex deposition (type III hypersensitivity) in small vessel forms, leading to complement activation and neutrophil recruitment. Triggers are categorized as:
- Idiopathic: No identifiable cause in up to 50% of cases.
- Infections: Streptococcal, viral (e.g., hepatitis B/C, HIV), or bacterial.
- Drugs: Common culprits include penicillin, sulfonamides, thiazides, and NSAIDs, typically appearing 7–14 days post-exposure.
- Autoimmune/connective tissue diseases: Rheumatoid arthritis, Sjögren syndrome, systemic lupus erythematosus.
- Malignancy: Paraneoplastic in lymphoproliferative disorders or solid tumors.
- Other: Serum sickness, food additives, or cryoglobulinaemia.
In skin-limited cases, the trigger often resolves spontaneously, but persistent antigens can lead to chronicity.
What are the clinical features of cutaneous vasculitis?
Skin lesions predominantly affect the lower legs (due to dependent areas), but can involve arms, trunk, or face. Key features include:
- Palpable purpura: Raised, non-blanching purple spots <5 mm (petechiae) or >5 mm (ecchymoses); hallmark of small vessel vasculitis.
- Urticarial vasculitis: Hive-like lesions lasting >24 hours, often burning rather than itchy.
- Erythema elevatum diutinum: Chronic fibrosing plaques on extensors.
- Nodular vasculitis: Tender subcutaneous nodules, mainly on calves.
- Medium vessel involvement: Retiform purpura, livedo, ulcers in cutaneous polyarteritis nodosa.
Systemic symptoms like fever, arthralgia, or myalgia occur in 40% but suggest possible extracutaneous involvement. Lesions evolve from erythematous macules to purpura, haemorrhagic blisters, necrosis, or ulceration over days, healing with hyperpigmentation or scarring.
How is cutaneous vasculitis diagnosed?
Diagnosis combines clinical presentation, history, and investigations:
- History: Recent drugs, infections, systemic symptoms.
- Examination: Lesion morphology, distribution, extracutaneous signs.
- Skin biopsy: Essential; shows leukocytoclastic vasculitis. Direct immunofluorescence (DIF) reveals immune complexes (IgG/IgM/C3 in vessel walls). Punch biopsy from early lesion (<48 hours) for optimal yield.
- Laboratory tests: CBC, ESR/CRP, urinalysis, ANA, ANCA, cryoglobulins, hepatitis serology, complement levels.
- Imaging: If systemic suspected (e.g., CT for malignancy).
Differential includes coagulopathies, infections (e.g., meningococcaemia), embolic phenomena, or pigmentary disorders.
What is the treatment for cutaneous vasculitis?
Treatment is guided by severity, chronicity, and systemic involvement. Most skin-limited cases (90%) are self-resolving in 3–4 weeks without systemic therapy.
General measures
- Leg elevation, rest, compression stockings to reduce oedema.
- Avoid triggers (discontinue drugs, treat infections).
- Topical corticosteroids/antihistamines for symptomatic relief.
- NSAIDs (e.g., ibuprofen) for pain.
Systemic therapy
| Clinical Scenario | Treatment |
|---|---|
| Initial mild episode (~90%) | Supportive care; systemic steroids if severe (prednisone 0.5–1 mg/kg/day, taper over 3–6 weeks) |
| Recurrent/chronic | Colchicine (0.6 mg BID), dapsone (50–150 mg/day), hydroxychloroquine |
| Ulcerative/severe | Glucocorticoids + immunosuppressants (methotrexate, azathioprine, mycophenolate) |
| Specific types (e.g., urticarial) | Dapsone, hydroxychloroquine, omalizumab, rituximab for refractory |
For systemic vasculitis, treat underlying disease (e.g., antivirals for hepatitis C-associated cryoglobulinaemia).
What is the outcome for cutaneous vasculitis?
Skin-limited cutaneous vasculitis has an excellent prognosis, with resolution in weeks to months and low recurrence risk (<10%). Chronic forms like erythema elevatum diutinum may persist years but respond to therapy. Systemic progression is rare (<10%), but mandates vigilant monitoring. Post-inflammatory hyperpigmentation fades over months; ulcers may scar.
Table 1. Classification of cutaneous vasculitis
| Type | Vessels | Key Features |
|---|---|---|
| Small vessel (CSVV) | Post-capillary venules | Palpable purpura, leukocytoclastic |
| Medium vessel | Muscular arteries | Nodules, livedo, ulcers (cPAN) |
| Urticarial | Small | Hives >24h, hypocomplementaemic |
| IgA (HSP) | Small | Purpura + arthritis/GI/renal |
Frequently asked questions
What triggers cutaneous vasculitis?
Common triggers include drugs (e.g., antibiotics), infections, autoimmune diseases, or idiopathic in many cases.
Is cutaneous vasculitis contagious?
No, it is an inflammatory condition, not infectious.
Does cutaneous vasculitis scar?
Mild purpura rarely scars; ulcerative lesions may leave atrophic scars.
When should I see a doctor?
If lesions persist >2 weeks, recur, or accompany systemic symptoms like fever, joint pain, or haematuria.
Can diet affect cutaneous vasculitis?
No strong evidence; avoid known allergens or triggers if identified.
References
- Treatment of cutaneous vasculitis — Chang YC, McMillen KA, et al. PMC – NIH. 2022-12-15. https://pmc.ncbi.nlm.nih.gov/articles/PMC9716566/
- Cutaneous Small-Vessel Vasculitis — Vasculitis Foundation. 2023-01-10. https://vasculitisfoundation.org/education/vasculitis-types/cutaneous-small-vessel-vasculitis/
- Cutaneous Vasculitis — NORD (National Organization for Rare Disorders). 2024-05-20. https://rarediseases.org/rare-diseases/cutaneous-vasculitis/
- Cutaneous vasculitis — DermNet NZ. 2023-10-01. https://dermnetnz.org/topics/cutaneous-vasculitis
- Cutaneous Vasculitis Information for Patients — Rheumatology Dermatology Society. 2023-08-15. https://www.rheumaderm-society.org/vasculitis-information-for-patients/
Similar Articles
Read full bio of Sneha Tete
